Lung Disease News and Research

RSS

First Edition: May 19, 2014

Today's headlines include a report about federal health care subsidies and an update on states small business health exchanges.

19 May 2014

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).

19 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

Novel molecule prevents symptoms linked with allergen-induced asthma

A new study carried out by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), the Max Planck Institute for Colloids and Interfaces (Germany), the Free University of Berlin (Germany), UC San Diego, and Shinshu University (Japan) has identified a novel molecule that prevents T-cells from orchestrating asthma brought on by allergens.

13 May 2014

Protein molecule seems to slow progression of deadly lung disease

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.

7 May 2014

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

While many parents-to-be are aware that the health of their baby starts before they've actually arrived into the world, recent research reveals that "harm" (i.e., tobacco smoke, dirty air, poor nutrition, even preeclampsia) may not present itself disease-wise until well into adulthood or when a second harmful "hit" triggers the individual's susceptibility.

6 May 2014

Boehringer announces first results of Phase III INPULSIS trials at 2014 ATS International Conference

Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 - 21 May in San Diego

30 Apr 2014

U of L School of Medicine researchers use breath analysis to detect lung cancer

Researchers at the University of Louisville School of Medicine are using breath analysis to detect the presence of lung cancer. Preliminary data indicate that this promising noninvasive tool offers the sensitivity of PET scanning, and has almost twice the specificity of PET for distinguishing patients with benign lung disease from those with early stage cancer.

30 Apr 2014

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF).

21 Apr 2014

Allergist says people allergic to multiple trees may have tough allergy this spring

The polar vortex may be on its way out, but it's certainly leaving its footprints behind. As spring rolls in, people allergic to multiple trees may have a tough allergy season - a consequence of the cold winter, says Mark Dykewicz, M.D., professor of allergy and immunology at Saint Louis University.

17 Apr 2014

S. pneumoniae serotypes differ between primary and post-viral disease

Certain capsular serotypes of Streptococcus pneumoniae are particularly likely to cause disease in people who have recently experienced a respiratory viral infection, study findings indicate.

14 Apr 2014

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis.

10 Apr 2014

SLU researcher receives $608,376 grant to design better clinical treatments for multiple sclerosis

Saint Louis University researcher Daniel Hawiger, M.D., Ph.D., has been awarded $608,376 from the National Multiple Sclerosis Society to gain a better understanding of how the autoimmune process that causes multiple sclerosis (MS) may be stopped or slowed down.

9 Apr 2014

SLU researcher receives NIH grant to study on type of opioids that lead to depression

After finding a link between chronic use of prescription-based painkillers and increase in risk of depression, Saint Louis University researcher Jeffrey Scherrer, Ph.D., has received a $391,706 NIH grant to further investigate the pattern in a wider patient base, and study the type of opioids that lead to depression.

8 Apr 2014

Researchers examine risks and benefits of E-cigarettes

Some believe e-cigarettes are less harmful than smoking tobacco since e-cig vapor doesn't contain the chemicals found in tobacco smoke.

3 Apr 2014

Research: Underweight puts people at highest risk of dying, just as obesity does

Being underweight puts people at highest risk of dying, just as obesity does, new research has found. The connection between being underweight and the higher risk of dying is true for both adults and fetuses.

29 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

Lung Disease News and Research

First Edition: May 19, 2014

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

Novel molecule prevents symptoms linked with allergen-induced asthma

Protein molecule seems to slow progression of deadly lung disease

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

Boehringer announces first results of Phase III INPULSIS trials at 2014 ATS International Conference

U of L School of Medicine researchers use breath analysis to detect lung cancer

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Allergist says people allergic to multiple trees may have tough allergy this spring

S. pneumoniae serotypes differ between primary and post-viral disease

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

SLU researcher receives $608,376 grant to design better clinical treatments for multiple sclerosis

SLU researcher receives NIH grant to study on type of opioids that lead to depression

Researchers examine risks and benefits of E-cigarettes

Research: Underweight puts people at highest risk of dying, just as obesity does

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

SLU researchers receive $1.4M grant to study alpha-1 antitrypsin deficiency in adults

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News